65,437 trials
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7 — 1.512; 1.389; 1.395; 1.286 Liters
Lymphoma
Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr
Multiple Sclerosis
Primary: Change From Baseline in Subscale Scores of the Fatigue Impact Scale — -3.74; -1.22; -4.24; -1.11 units on a scale — p=<0.05
Melanoma
Primary: Number of Patients With Response — 0; 2; 14; 15 participants
Cocaine Dependence
Primary: Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back — 13; 7 participants — p==.05
Brain and Central Nervous System Tumors · Cognitive/Functional Effects · Long-term Effects Secondary to Cancer Therapy in Children
Primary: Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks — 10 units on a scale
Heart Failure, Congestive · Chronic Heart Failure · Depression
Primary: Symptoms of Depression in Congestive Heart Failure Patients With Clinical Depression After Treatment With Sertraline or Placebo — -7.1; -6.8 HDRS Change Score — p=0.89
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Multiple Myeloma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants
Lung Cancer
Primary: Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease — 4.7…
Benign Prostatic Hyperplasia · Enlarged Prostate
Primary: Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks — -5.18; -3.76 units on a scale — p=0.001
Postoperative Pulmonary Atelectasis · Surgery
Primary: Alveolar - Arterial Gradient — 70.6; 134 torr
Continuous Ambulatory Peritoneal Dialysis · End Stage Renal Disease
Primary: Volume of Distribution, Central Compartment (Vc) — 2.78 Liters (L)
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT — 65.2 percentage of participant with DC
Healthy Subjects
Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series — 100.0…